Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2019-05-23 Regulatory Filings
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys to Present at Upcoming Investor Conferences (news with additional features)
Regulatory Filings Classification · 99% confidence The document is a news release dated May 23, 2019, announcing that MorphoSys AG will be presenting at several upcoming investor conferences (Jefferies, dbAccess, Goldman Sachs, J.P. Morgan) and hosting a 'Meet the Team' event. The content explicitly lists dates, venues, and presenters for these events. This type of announcement, which informs investors about management's schedule for engaging with the investment community, is best classified as an Investor Presentation announcement or related communication, which aligns most closely with the 'Investor Presentation' (IP) category, as it details future opportunities for investors to hear presentations from management. Although it is an announcement about future presentations rather than the presentation itself, it is a direct communication regarding investor engagement activities.
2019-05-23 English
MorphoSys AG Reports Outcome of Annual General Meeting 2019 (news with additional features)
AGM Information Classification · 99% confidence The document explicitly states in the title and body: "MorphoSys AG Reports Outcome of Annual General Meeting 2019". It details the resolutions approved by shareholders at the AGM, including board appointments and capital structure changes related to the meeting. This directly corresponds to the definition of AGM Information (AGM-R). Although it mentions voting results, the primary focus is reporting the overall outcome and context of the Annual General Meeting itself, rather than just the formal declaration of results (DVA).
2019-05-22 English
MorphoSys AG: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity (news with additional features)
Regulatory Filings Classification · 95% confidence The document is a news release dated May 16, 2019, announcing the primary endpoint results of a clinical study (L-MIND) for the drug Tafasitamab (MOR208). It details efficacy metrics (ORR, CR rate, mPFS, mDoR) and mentions plans for a future BLA submission and a Q&A session. This content strongly aligns with an Earnings Release (ER) which typically announces key periodical financial or operational results, although this is a clinical trial update. However, since the document is a direct announcement of key operational/study results, and not a comprehensive report (like 10-K or IR), the best fit among the provided options is 'ER' (Earnings Release), as clinical trial milestones are often treated as key performance indicators announced via this channel, especially when they precede regulatory filings. It is not a transcript (CT), a full annual report (10-K), or a general regulatory filing (RNS) given the specific nature of the announcement. It is an announcement of results, not an announcement *about* a report being published (RPA).
2019-05-16 English
MorphoSys AG: Ad hoc: Primary Endpoint of L-MIND, a Combination Study of Tafasitamab (MOR208) and Lenalidomide, has been met, Confirming Previously Published Activity
Regulatory Filings Classification · 98% confidence The document is explicitly labeled as an "Ad-hoc" release and states "Ad hoc release according to article 17 MAR". Article 17 of the Market Abuse Regulation (MAR) mandates the immediate public disclosure of inside information by issuers. This type of announcement, which conveys critical, non-scheduled, price-sensitive information (in this case, clinical trial results), is typically classified as a general regulatory announcement or a specific type of earnings/material event disclosure. Since it is not a full financial report (10-K, IR), a transcript (CT), or a formal earnings release (ER) focusing only on key highlights, and it is a mandatory disclosure under EU regulation, it fits best under the general regulatory filing category, RNS, which serves as a fallback for miscellaneous regulatory announcements not covered by more specific codes like DIV or DIRS. The document length is substantial (over 10,000 characters), indicating it is the primary content, not just a brief announcement of a report (which would suggest RPA).
2019-05-16 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Notification of Major Holdings' and details changes in voting rights percentages held by FMR LLC and its subsidiaries, referencing specific German securities law (WpHG). This type of filing, which reports changes in significant share ownership thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is disseminated via DGAP (which might suggest RNS), the specific content is a mandatory disclosure of ownership change, making MRQ the most precise classification.
2019-05-14 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed sections regarding the 'Notification of Major Holdings' under German securities law (WpHG). It details changes in the percentage of voting rights held by FMR LLC and its subsidiaries, crossing specific thresholds (8.95% new total). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels. Reviewing the definitions: - 10-K/IR: Not a full annual or interim financial report. - ER: Not an earnings release. - DIV/CAP/SHA: Not primarily about dividends, financing, or general share issuance. - DVA: This is related to voting rights, but DVA is specifically for *results* of a shareholder vote, whereas this is a notification of *holding* changes. - MRQ (Major Shareholding Notification): This category perfectly matches the content, which tracks changes in significant share ownership levels (crossing thresholds) as mandated by securities regulations (WpHG in this case).
2019-05-09 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.